December 14, 2023
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
Vietnam has set a target of becoming a high-value pharmaceutical production center in the region under its strategy for the development of the pharmaceutical sector by 2030 with a vision to 2045.
Under the strategy, which was approved by Deputy Prime Minister Tran Hong Ha on October 9, Vietnam will strive to develop its pharmaceutical industry to be on par with those in advanced countries in the region while ensuring people’s access to medicines at affordable prices.
It will improve its research capacity and optimize existing technologies to produce generic medicines and modern dosage forms, a part of becoming a center for the technology transfer and manufacture of generic drugs in ASEAN.
Vietnam also targets the mass production of pharmaceuticals and products from domestic medicinal resources with high quality and value, and will boost the production of raw materials.
Other goals under strategy include achieving WHO certification at Level 3 or higher in the capacity of State management over pharmaceutical products, and maintain and upgrade WHO certification on the capacity of State management over vaccines.
All pharmaceutical businesses meeting good manufacturing practice (GMP) standards will be maintained, while all drug and vaccine testing facilities are to follow good laboratory practice (GLP) principles.
Source: https://vneconomy.vn
About STELLAPHARM
Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com
Thành phố Hồ Chí Minh và Geneva, ngày 10 tháng 9 năm 2026 – Stellapharm và Medicines Patent Pool (MPP) ký Thỏa thuận cấp phép (Sublicence Agreement) về việc phát triển, sản xuất và cung ứng thuốc generic chứa hoạt chất baloxavir marboxil do Roche nắm sở hữu bản quyền. Đây là thuốc kháng virus
Ho Chi Minh City and Geneva, 10 September 2026 – Stellapharm and Medicines Patent Pool (MPP) signed a sublicence agreement to develop, manufacture and supply a generic version of Roche’s baloxavir marboxil, a single-dose antiviral treatment recommended by the World Health Organization (WHO) for influenza. The agreement will allow Stellapharm to manufacture and supply baloxavir